LifeVantage Corporation — Form 10-Q Summary
Reporting period: Fiscal first quarter ended September 30, 2023; comparisons are with the three months ended September 30, 2022 unless otherwise noted. The company sells nutritional supplements, personal-care and related products through independent consultants and direct-to-consumer channels. Amounts below are in millions except per-share data.
Key financial results
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Revenue | $51.4 | $51.8 | Down 0.8% |
| Gross profit / margin | $41.2 / 80.2% | $41.8 / 80.8% | Margin down 0.6 percentage points |
| Operating income | $0.7 | $1.3 | Down $0.5 |
| Net income | $0.6 | $0.6 | Up $0.02 |
| Diluted EPS | $0.05 | $0.05 | No change |
| Operating cash flow | $4.8 | $(1.3) | Improved $6.1 |
| Capital expenditures | $1.1 | $0.7 | Cash outflow |
| Cash and cash equivalents | $18.4 at September 30 | $21.6 at June 30, 2023 | Down $3.2 |
| Working capital | $17.2 at September 30 | $24.7 at June 30, 2023 | Down $7.5 |
There was no outstanding balance on the company’s revolving credit facility at quarter-end. The facility provides up to $5.0 million of borrowing capacity, carries an effective rate of 8.55% if drawn, and matures March 31, 2024. The company reported compliance with its financial covenants.
Business trends and changes versus prior period
- Americas revenue increased 5.9% to $38.5 million, including U.S. growth of 6.5%. Asia/Pacific & Europe revenue declined 16.6% to $12.9 million.
- TrueScience Liquid Collagen revenue, including bundle sales, was approximately $10.0 million versus $7.1 million a year earlier, supporting higher average revenue per account in the Americas.
- Active consultants declined 17.5% to 52,000, active customers fell 5.6% to 85,000, and total active accounts decreased 10.5% to 137,000.
- Asia/Pacific & Europe weakness reflected fewer active accounts, foreign-exchange headwinds and the March 2023 closure of the company’s China e-commerce business. Greater China revenue fell 60.4%.
- Commissions and incentives declined to 43.8% of revenue from 46.0%, attributed partly to the Evolve Compensation Plan launched in March 2023 in the U.S., Japan, Australia and New Zealand, and to promotional timing.
- SG&A increased to 35.0% of revenue from 32.3%, primarily due to higher legal and stock-based compensation expense. Higher raw-material, manufacturing, shipping and fulfillment costs, along with product mix, reduced gross margin.
Liquidity, capital allocation and outlook
Operating cash flow was positive, but financing outflows of $6.7 million—principally the $5.5 million dividend, share repurchases and tax withholding on equity awards—contributed to the quarterly cash decline. The dividend included a one-time $0.40 per-share payment and the regular $0.035 per-share quarterly dividend. The company repurchased approximately 0.1 million shares for $0.8 million; $26.1 million remained under its $60 million repurchase authorization.
Management believes cash and ongoing operating cash flow will be sufficient for requirements over at least the next 12 months. It also noted that additional financing may not be available on acceptable terms and that credit-facility covenants restrict certain financing and capital-return actions. The filing provides no specific revenue or earnings guidance.
Risks, contingencies and unusual items
- The company’s business depends on attracting and retaining consultants and customers; the substantial decline in active accounts is an important demand indicator.
- Foreign exchange, market-specific declines, product concentration, supply-chain and inventory management, regulatory compliance, product claims, cybersecurity and competition are among the disclosed business risks.
- Management reported no probable loss contingencies requiring accrual or disclosure. It noted that legal matters and unfavorable publicity could affect results, while stating it did not currently expect other incidental matters to have a material adverse effect.
- A stockholder Rights Plan adopted in August 2023 generally becomes exercisable if a person acquires 12% or more of the common stock (20% for passive investors). It expires August 24, 2024 unless earlier terminated, redeemed or exchanged; the filing says it had no current financial-statement impact.
- Disclosure controls were assessed as effective, and management reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the decline in consultant and customer accounts continues, and whether Liquid Collagen and other launches can offset it sustainably.
- Revenue and account trends in Asia/Pacific & Europe, including Japan and the post-closure China business, separated from foreign-exchange effects.
- Whether gross margin stabilizes as product mix and input, shipping and fulfillment costs change.
- Cash generation after dividends and repurchases, and the implications of the lower working-capital balance and the March 2024 credit-facility maturity.
- Any developments in legal, regulatory or tax matters, Rights Plan provisions, and the company’s ability to maintain covenant compliance while making capital returns.